Poll: Do You Feel Prepared to Prescribe the Newly Approved First-In-Class Muscarinic Agonist?

On September 26, 2024, the US Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride), formerly known as KarXT, for the treatment of schizophrenia in adults. In doing so, it represents the first drug with a novel mechanism in decades, as it selectively targets the M1 and M4 receptors without blocking D2 receptor.

The landmark decision brings excitement to the field. “[The] landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm,” Chris Boerner, PhD , board chair and chief executive officer at Bristol Myers Squibb said in a press release.¹ “As we reenter the field of neuropsychiatry, we are dedicated to changing the conversation around serious mental illness, beginning with today’s approval in schizophrenia.”

Although Psychiatric Times and other medical publications have reviewed the research leading to the approval, how prepared are clinicians to discuss the agent with patients and consider its use in regular practice?

Stay up to date with the latest research by subscribing to Psychiatric Times e-newsletters.

Reference

1. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults. BMS. Press release. September 26, 2024. Accessed September 27, 2024. https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-COBENFY-xanomeline-and-trospium-chloride-a-First-In-Class-Muscarinic-Agonist-for-the-Treatment-of-Schizophrenia-in-Adults/default.aspx